Abstract: Objective To study the clinical value of intravenous co-therapy and extended initial phase therapy in first retreatment pulmonary tuberculosis patients. Methods The cases were randomly divided into therapy group 1(132 cases) and therapy group 2 (95 cases) , group 1 was treated with 2AHPRZE/6HRE. and received intravenous co-therapy in initial phase，while group 2 was treated with 2SHRZE/1HRZE/5HRE. Resulls Within 1 month, symptoms were effectively alleviated in group 1. The symptoms of fever, cough，sputum and weak were greatly improved, the disappeared rate was from 76. 23% to 87. 50%，P<0. 01. After 1 month of treatment, the tuberculosivs sputum smear negative conversion rate in group 1 was 80. 90%，while the group 2 was 59. 02 %，PP<0.05. Although the final conversion rate in group 1 was higher than that in group 2，there was no statistical difference between the two groups. Throughout the course of treatment,the effective rate of focus absorption in group 1 was 73. 48% which was better than group 2 (51. 58%) ,P<0. 01. After 1 month of treatment, the rate of cavity shrankage in group 1 was 66. 07%, while group 2 was 36.36 % , P<0. 01. At the end of treatment, the rate of cavity closure was 62. 50%，higher than that in group 2，which was 36. 36 % , P<0.05. Conclusions Both intravenous co-therapy and extended initial phase therapy can improve the therapeutic effect, the former is better.

Key words: tuberculosis, pulmenary/drug therapy, infusions, intravenous, treahmenl outcome